Made With Uberflip Content Marketing

Medtech

  • Breaking down the “four walls” of patient care: What is the state of the digital medicine industry?

    Breaking down the “four walls” of patient care: What is the state of the digital medicine industry?

    Amid tirelessly pursuing possible partnerships and investment opportunities to bring revolutionary medical products to market at Biotech Showcase™ 2017 in San Francisco, global executives were...

    Read
  • Finding Finance: Pharma, Biotech & Medtech Capital Raising 2016

    Finding Finance: Pharma, Biotech & Medtech Capital Raising 2016

    Read Flipbook
  • Industry pundit Joe Hage on medtech innovation in 2017

    Industry pundit Joe Hage on medtech innovation in 2017

    Joe Hage, a medical device marketing consultant, is well known in medtech circles. In particular, he runs one of the largest and possibly most successful LinkedIn groups, the “Medical Devices...

    Read
  • Digital Health: Still a brave new world

    Digital Health: Still a brave new world

    At this year’s BIO-Europe Spring® panel on “The Convergence of Therapeutics and Digital Health,” two panelists from big pharma joined two from Scandinavian digital health companies, agreeing that...

    Read
  • Where you build your healthcare IP is just as important as how you build it

    Where you build your healthcare IP is just as important as how you build it

    Guest post by Ben Ball, Business Development Manager, Australian Consulate-General   For most businesses, intellectual property is the foundation you build on. Transforming an idea into a product...

    Read
  • Still unsure about China? FT article highlights rise in China pharma R&D, innovation

    Still unsure about China? FT article highlights rise in China pharma R&D, innovation

    What is China’s real potential for R&D and innovative “breakthrough” products? February 18 article by Andrew Ward in London and Patti Waldmeir in Shanghai in Financial Times reported on recent...

    Read
  • Medtech Showcase: State of the Industry 2016

    Medtech Showcase: State of the Industry 2016

    Healthcare is converging, bringing together traditional therapeutics, precision medicine, combination products and companion diagnostics that require insightful approval and reimbursement...

    Read
  • Why does your company need a press release to announce participation in an upcoming event?

    Why does your company need a press release to announce participation in an upcoming event?

    In a digital world, do press releases still have relevance? Before social media took over as the top source for breaking news, the telegraph ruled, driven to prominence during the 1800s to meet...

    Read
  • Tips from investors for presenting your company to get real results

    Tips from investors for presenting your company to get real results

    With Biotech Showcase™ just four weeks away, public and private mid-, small- and micro-cap publicly-traded life science companies, as well as private life science companies, need to start thinking...

    Read
  • Differentiation is a key strategy for medtech companies

    Differentiation is a key strategy for medtech companies

    The recent EY Pulse of the Industry Report made the case that the commoditization of many medtech product segments is transforming the medical device sector. The report stated that for medtech...

    Read
  • Addressing Investor Needs as the Life Sciences Ecosystem Expands

    Addressing Investor Needs as the Life Sciences Ecosystem Expands

    Guest post by Sara Jane Demy, CEO, Demy-Colton Life Science Advisors With the unofficial arrival of Fall comes the time to dust the sand off our feet and focus on getting deals done before the end...

    Read
  • Why Japan medtech? Why now?

    Why Japan medtech? Why now?

    Japan is an extremely hot medtech market; they are the world’s third largest importer of medical devices and are among the world’s top 10 largest medical device exporters, according to a report...

    Read
  • What to look for in companies navigating drug approval processes on both sides of the pond

    Guest post by Jim Patrick, Publisher, The Life Sciences Report What moves biotech stocks the most and is it different in the US than it is in Europe? According to The Small-Cap Biotech Watchlist...

    Read
  • Spotlight on the MedTech Industry

    The Medtech Trends and MoneyTree™ Investment Data report has recently been published and the medtech industry is profiting from more deals – however, the number of medtech companies receiving...

    Read
  • Japan’s newest international life science business-to-business conference comes to Tokyo in May 2015

    Japan’s newest international life science business-to-business conference comes to Tokyo in May 2015

    Despite its reputation for prolific and innovative technology development and its increasing ageing population, Japan has largely been left behind in the medical device field. Why? According to a...

    Read
  • Find your next drug development partner in Paris

    Find your next drug development partner in Paris

    Who doesn’t love Paris? Food, culture, fashion. The Eiffel Tower. But did you know that Paris is the number one region for developing startups in Western Europe, a leader in clinical research,...

    Read
  • Partnerships are powerful in moving from apps to medical devices

    Partnerships are powerful in moving from apps to medical devices

    According to PricewaterhouseCooper, one of the top trends to keep an eye on next year in the healthcare field is the evolving role of medical apps moving to medical devices.  Next year, the FDA is...

    Read
  • Puerto Rico is the new hot life sciences manufacturing location

    Puerto Rico is the new hot life sciences manufacturing location

    Latin America has been on the radar of global biopharma companies and investors for years, but tax incentives and credits have firmly established a place for Latin American countries in the future...

    Read
  • Innovative funding for small and medium enterprises in Europe

    With the shortage of early stage life sciences funding, the role of government in funding the next generation of cures is becoming increasingly important. In January 2014, the European Union...

    Read
  • loading
    Loading More...